On Jan. 11, 2022, GlaxoSmithKline and Vir Biotechnology announced the US Government had purchased an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, enabling further nationwide access to sotrovimab for patients.

The additional 600,000 doses were to be delivered throughout the first quarter of 2022. This agreement was an amendment to earlier commitments announced with the US Government in November 2021.